PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.

被引：5

作者：

Abou-Alfa, Ghassan K.

Borbath, Ivan

Roychowdhury, Sameek

Goyal, Lipika

Lamarca, Angela

Macarulla, Teresa

Shroff, Rachna T.

Oh, Do-Youn

Javle, Milind M.

Tamas, Catalin

Savastano, David M.

Van Veenhuyzen, David Friedrich

Xu, Cindy

Solanas, Jacki

Freas, Elizabeth

机构：

[1] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Catholic Univ Louvain, Brussels, Belgium

[4] James Canc Hosp, Ohio State Comprehens Canc Ctr, Columbus, OH USA

[5] Harvard Med Sch, Canc Ctr, Dept Med, Massachusetts Gen Hosp, Boston, MA USA

[6] Fdn Jimenez Diaz Univ Hosp, Madrid, Spain

[7] Vall dHebron Univ Hosp, Gastrointestinal & Endocrine Tumor Unit, Barcelona, Spain

[8] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[9] Univ Arizona, Canc Ctr, Tucson, AZ USA

[10] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea

[11] Seoul Natl Univ, Grad Sch, Natl Univ Coll Med, Integrated Major Innovat Med Sci, Seoul, South Korea

[12] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA

[13] Helsinn Healthcare SA, Lugano, Switzerland

[14] Helsinn Therapeut US Inc, Iselin, NJ USA

[15] QED Therapeut Inc, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

298-145-222-184-4809-11811; 11890-11946-11936; 261-566-148; 261-492-5651-9270-10662; 261-492-3532-2370-7650-2700; 130-540-543-4790; 261-492-3532-2370-5109; 4; 3; 2; 3229; 3590; 297; 176; 62; 9; 1; 38092-23140; 38092-34311; 38116-38094-8; 38092-20175;

D O I：

10.1200/JCO.2024.42.3_suppl.516

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：516 / 516

页数：1